
|Videos|June 18, 2015
Effect of Anamorelin on Cachexia in Advanced NSCLC
Author(s)Jennifer S. Temel, MD
Jennifer S. Temel, clinical director, Thoracic Oncology, Massachusetts General Hospital, discusses a phase III study that examined the impact of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL
3
Earlier Cilta-Cel Improves Myeloma Outcomes Via Enhanced Immune Fitness
4
Odronextamab Plus CHOP Shows Promise in Early Phase 3 Data for Untreated DLBCL
5









































